Shield Therapeutics plc (STX.L)
- Previous Close
2.3500 - Open
2.2950 - Bid 2.2000 x --
- Ask 2.5000 x --
- Day's Range
2.2950 - 2.5000 - 52 Week Range
0.0249 - 5.8700 - Volume
914,134 - Avg. Volume
1,971,230 - Market Cap (intraday)
27.704M - Beta (5Y Monthly) 1.22
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date Apr 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
13.73
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.
www.shieldtherapeutics.com63
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: STX.L
View MorePerformance Overview: STX.L
Trailing total returns as of 5/19/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: STX.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: STX.L
View MoreValuation Measures
Market Cap
24.48M
Enterprise Value
39.40M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.76
Price/Book (mrq)
--
Enterprise Value/Revenue
1.63
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-84.47%
Return on Assets (ttm)
-26.90%
Return on Equity (ttm)
-396.36%
Revenue (ttm)
32.18M
Net Income Avi to Common (ttm)
-27.18M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
6.52M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-12.05M